Condition: Cardiometabolic Disease · Sponsor: Amgen
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Anaheim Clinical Trials | Anaheim, California, United States | Recruiting |
| Orange County Research Center | Lake Forest, California, United States | Recruiting |
| Fomat Medical Research | Oxnard, California, United States | Recruiting |
| Translational Clinical Research LLC | Aventura, Florida, United States | Recruiting |
| Clinical Neuroscience Solutions - Jacksonville | Jacksonville, Florida, United States | Recruiting |
| New Horizon Research Center | Miami, Florida, United States | Recruiting |
| Clinical Pharmacology of Miami, LLC | Miami, Florida, United States | Recruiting |
| Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group | Union City, Georgia, United States | Recruiting |
| Lillestol Research LLC | Fargo, North Dakota, United States | Recruiting |
| Pinnacle Clinical Research | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06585462